Sund L J, Wood D M, Archer J R H, Blundell M S, Dargan P I
From the Emergency Medicine, Guy's and St Thomas' NHS Foundation Trust and King's Health Partners, London, UK.
Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust and King's Health Partners, London, UK.
QJM. 2023 Feb 24;116(2):99-106. doi: 10.1093/qjmed/hcac220.
Vaping of cannabinoid-based products and informal acquisition of vaping products were associated with the outbreak of E-cigarette or vaping associated lung injury (EVALI) in the USA. Current prevalence of cannabinoid-based vaping within the UK is not known and literature regarding the acquisition of vaping products is limited.
To estimate the prevalence of nicotine-based, nicotine-free and cannabinoid-based product vaping within the UK and to determine where vaping products are acquired.
A voluntary online survey of individuals aged 16 and over within the UK was conducted using a convenience sample. Data were collected on respondent demographics, smoking/vaping history and acquisition of e-liquids/products.
A total of 2478 responses were included. Median age 45 years (interquartile range 35-57). Prevalence of current vaping of nicotine-based e-liquids, nicotine-free e-liquids and cannabinoid-based products was 14.4%, 11.2% and 5.49%, respectively. Current nicotine-based and nicotine-free vaping was most prevalent in 25-34 years olds (22.4% and 19.2% of respondents). Current cannabinoid-based vaping was most prevalent in 16-24 years olds. The most common 'ever' used cannabinoid-based products were cannabidiol oil/cannabigerol oil and cannabis leaves (4.8%). Specialist vaping stores were the most common source of 'ever' acquisition for all products. 36.8% and 40.5% of respondents who had ever vaped nicotine-based and nicotine-free e-liquids reported prior acquisition from informal sources.
This survey reported a higher prevalence of current cannabinoid-based vaping within the UK (5.5%) than previously reported in the USA (2.0%). In addition to the informal acquisition of vaping products as demonstrated within the survey, these results highlight potential underestimation of the risk of EVALI within the UK.
在美国，吸食基于大麻素的产品以及非正式获取电子烟产品与电子烟或雾化相关肺损伤（EVALI）的爆发有关。目前英国基于大麻素的雾化产品的流行情况尚不清楚，关于获取电子烟产品的文献也很有限。
估计英国使用含尼古丁、不含尼古丁和基于大麻素产品进行雾化的流行率，并确定获取电子烟产品的地点。
采用便利抽样法，对英国16岁及以上人群进行了一项自愿在线调查。收集了受访者的人口统计学信息、吸烟/雾化历史以及电子液体/产品的获取情况。
共纳入2478份回复。中位年龄45岁（四分位间距35 - 57岁）。目前使用含尼古丁电子液体、不含尼古丁电子液体和基于大麻素产品进行雾化的流行率分别为14.4%、11.2%和5.49%。目前使用含尼古丁和不含尼古丁雾化产品的情况在25 - 34岁人群中最为普遍（分别占受访者的22.4%和19.2%）。目前基于大麻素的雾化在16 - 24岁人群中最为普遍。最常见的“曾经”使用过的基于大麻素的产品是大麻二酚油/大麻萜酚油和大麻叶（4.8%）。专业电子烟商店是所有产品“曾经”获取的最常见来源。曾经吸食过含尼古丁和不含尼古丁电子液体的受访者中，分别有36.8%和40.5%报告此前是从非正式渠道获取的。
本次调查显示，英国目前基于大麻素的雾化流行率（5.5%）高于美国此前报告的流行率（2.0%）。除了调查中显示的非正式获取电子烟产品的情况外，这些结果凸显了英国可能低估了EVALI的风险。
